News
Market and company headlines
ARQTAll
Loading
16:00Oct 211 Story
06:00Oct 201 Story
19:00-23:00Oct 192 Stories
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
Arcutis Biotherapeutics (NASDAQ:ARQT) saw its share price jump by 10.65 percent to close at $31.89 apiece after earning a bullish outlook and a double-digit price target hike from an analyst. In its market note, investment firm Guggenheim upgraded its stock target by 15.8 percent to $44 from $38 previously, while keeping a buy recommendation. It […]
Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock
Arcutis Biotherapeutics reported past conference data on its ZORYVE portfolio, including Phase 2 INTEGUMENT-INFANT results in atopic dermatitis and multiple analyses across creams and foams for plaque psoriasis and seborrheic dermatitis, covering different strengths, formulations, and approved age ranges. The breadth of ZORYVE data across age groups, formulations, and special sites illustrates the extent to which Arcutis Biotherapeutics relies on a single franchise to support future...
08:00-14:00Oct 192 Stories
Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027
Key TakeawaysArcutis shares rose 12% after Guggenheim raised its price target to $44 from $38 and kept its Buy rating, citing “growing conviction” about 2027. It’s the second bullish call in a week, after Cantor Fitzgerald started coverage on Thursday with an Overweight rating and a $48 target.
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.
02:00-11:00Oct 152 Stories
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.
01:00Oct 101 Story
04:00-09:00Oct 92 Stories
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limitedNew analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's efficacy and symptom improvements across the body in individuals with psoriasisAdditional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitisReal-world research examines the role lon
Arcutis Presents ZORYVE Data At EADV Congress
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limitedNew analyses from the ARRECTOR and DERMIS-1/2 trials
04:00-09:00Oct 62 Stories
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Newly created award category highlights innovation in prescription skin treatmentZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the awardZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq
Arcutis Biotherapeutics: An Emerging GARP Stock
Arcutis Biotherapeutics stock analysis: ZORYVE growth drives profit shift, raises FY2026 sales guide, and has strong cash flow & EPS outlook. Click for more on ARQT stock.
23:00Oct 51 Story
16:00Oct 21 Story
05:00Oct 11 Story
09:00Sep 291 Story
07:00-17:00Sep 213 Stories
AXT Inc. (AXTI) Climbs 16% on S&P 600 Addition
AXT Inc. (NASDAQ:AXTI) extended its winning streak to a fifth straight day on Monday, surging by as much as 16.4 percent in intraday trading to $81.50, as investors resumed buying positions amid its official membership in the S&P 600 index. Effective on the same day, the listed firm officially joined the S&P 600 index alongside […]
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential
Arcutis Biotherapeutics (ARQT) offers strong growth, reasonable industry valuation, and decent financial health—key affordable growth traits.
04:00Sep 191 Story
10:00Sep 172 Stories
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
03:00Sep 171 Story
12:00Sep 161 Story
06:00Sep 71 Story
05:00Aug 191 Story
06:00Aug 141 Story
07:00Aug 111 Story
09:00Aug 62 Stories
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
Arcutis Biotherapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Arcutis Biotherapeutics, Inc.
08:00Aug 62 Stories
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Arcutis Biotherapeutics, Inc.'s Q2 2026 earnings call
03:00-06:00Aug 62 Stories
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
